In Q1 2023, Commodore Capital held 25 positions worth $438.7M. They initiated 25 new positions. Their largest holding was XENE ($66.0M).
Frequently asked questions
What stocks did Commodore Capital own in Q1 2023?
Commodore Capital held 25 biotech stocks in their 13F portfolio in Q1 2023. Their top positions include XENE, COGT, ELVN, AKRO, NUVL. The full holdings table is available on BiotechEdge with position sizes, quarter-over-quarter changes, and AI analysis.
How much was Commodore Capital's portfolio worth in Q1 2023?
Commodore Capital's tracked biotech portfolio was worth $438.7M across 25 positions, with total assets under management of approximately $1.5B. Portfolio values are based on 13F filings with the SEC.
What did Commodore Capital buy in Q1 2023?
Commodore Capital initiated 25 new positions in Q1 2023, including XENE, COGT, ELVN, AKRO, NUVL and 20 more. They also increased 0 existing positions.
What did Commodore Capital sell in Q1 2023?
Commodore Capital did not fully exit any positions in Q1 2023.
Is Commodore Capital a biotech fund?
Healthcare-focused investment firm co-founded by Egen Atkinson and Michael Kramarz. Takes concentrated positions in biotech and life sciences companies, combining deep scientific analysis with active portfolio management.
Want AI analysis, insider signals, and catalyst overlays for Commodore Capital?
View latest Commodore Capital portfolio →